Media stories about Sienna Biopharm (NASDAQ:SNNA) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sienna Biopharm earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1084753874198 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several research analysts recently issued reports on SNNA shares. BMO Capital Markets started coverage on shares of Sienna Biopharm in a research report on Monday, August 21st. They set an “outperform” rating and a $30.00 price target on the stock. Cowen and Company began coverage on shares of Sienna Biopharm in a research report on Monday, August 21st. They set an “outperform” rating and a $50.00 target price on the stock. Finally, J P Morgan Chase & Co began coverage on shares of Sienna Biopharm in a research report on Monday, August 21st. They set an “overweight” rating and a $28.00 target price on the stock.

Sienna Biopharm (SNNA) traded down 5.51% on Thursday, reaching $25.02. 201,279 shares of the company’s stock were exchanged. Sienna Biopharm has a 52 week low of $18.50 and a 52 week high of $29.25. The stock’s 50 day moving average is $21.15 and its 200 day moving average is $21.15.

In other news, insider Paul F. Lizzul acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average price of $15.00 per share, for a total transaction of $150,000.00. Following the completion of the acquisition, the insider now directly owns 94,634 shares in the company, valued at approximately $1,419,510. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Keith R. Leonard acquired 16,700 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average price of $15.00 per share, with a total value of $250,500.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 48,700 shares of company stock valued at $730,500.

ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/sienna-biopharm-snna-receiving-somewhat-favorable-press-coverage-report-finds/1534940.html.

Sienna Biopharm Company Profile

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with Analyst Ratings Network's FREE daily email newsletter.